Literature DB >> 29895504

Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.

Patrizio Pezzotti1, Alessandro Miglietta2, Arianna Neri1, Cecilia Fazio1, Paola Vacca1, Fabio Voller3, Giovanni Rezza1, Paola Stefanelli4.   

Abstract

INTRODUCTION: In Tuscany, Italy, where a universal immunization program with monovalent meningococcal C conjugate vaccine (MCC) was introduced in 2005, an outbreak of invasive meningococcal disease (IMD) due to the hypervirulent strain of Neisseria meningitidis C/cc11 occurred in 2015-2016, leading to an immunization reactive campaign using either the tetravalent (ACWY) meningococcal conjugate or the MCC vaccine. During the outbreak, IMD serogroup C (MenC) cases were also reported among vaccinated individuals. This study aimed to characterize meningococcal C conjugate vaccines (MenC-vaccines) failures and to estimate their effectiveness since the introduction (2005-2016) and during the outbreak (2015-2016).
METHODS: MenC cases and related vaccine-failures were drawn from the National Surveillance System of Invasive Bacterial Disease (IBD) for the period 2006-2016. A retrospective cohort-study, including the Tuscany' population of the birth-cohorts 1994-2014, was carried out. Based on annual reports of vaccination, person-years of MenC-vaccines exposed and unexposed individuals were calculated by calendar-year, birth-cohort, and local health unit. Adjusted (by birth-cohort, local health unit, and calendar-year) risk-ratios (ARR) of MenC invasive disease for vaccinated vs unvaccinated were estimated by the Poisson model. Vaccine-effectiveness (VE) was estimated as: VE = 1-ARR.
RESULTS: In the period 2006-2016, 85 MenC-invasive disease cases were reported; 61 (71.8%) from 2015 to 2016. Twelve vaccine failures occurred, all of them during the outbreak. The time-interval from immunization to IMD onset was 20 days in one case, from 9 months to 3 years in six cases, and ≥7 years in five cases. VE was, 100% (95%CI not estimable, p = 0.03) before the outbreak (2006-2014) and 77% (95%CI 36-92, p < 0.01) during the outbreak; VE was 80% (95%CI 54-92, p < 0.01) during the overall period.
CONCLUSIONS: In Tuscany, MenC-vaccine failures occurred exclusively during the 2015-2016 outbreak. Most of them occurred several years after vaccination. VE during the outbreak-period was rather high supporting an effective protection induced by MenC-vaccines.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Invasive meningococcal disease; Meningococcal C conjugate vaccine; Outbreak; Vaccine effectiveness

Mesh:

Substances:

Year:  2018        PMID: 29895504     DOI: 10.1016/j.vaccine.2018.06.002

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Carbohydrate based meningococcal vaccines: past and present overview.

Authors:  Francesco Berti; Maria Rosaria Romano; Francesca Micoli; Roberto Adamo
Journal:  Glycoconj J       Date:  2021-04-27       Impact factor: 2.916

2.  Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children.

Authors:  Marzia Monica Giuliani; Alessia Biolchi; Pavitra Keshavan; Maria Moriondo; Sara Tomei; Laura Santini; Elena Mori; Alessandro Brozzi; Margherita Bodini; Francesco Nieddu; Silvia Ricci; Thembile Mzolo; Marco Costantini; Chiara Azzari; Michele Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

3.  Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.

Authors:  Myint Tin Tin Htar; Sally Jackson; Paul Balmer; Lidia Cristina Serra; Andrew Vyse; Mary Slack; Margarita Riera-Montes; David L Swerdlow; Jamie Findlow
Journal:  BMC Public Health       Date:  2020-12-09       Impact factor: 3.295

4.  Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.

Authors:  Milou Ohm; Susan J M Hahné; Arie van der Ende; Elisabeth A M Sanders; Guy A M Berbers; Wilhelmina L M Ruijs; Nina M van Sorge; Hester E de Melker; Mirjam J Knol
Journal:  Clin Infect Dis       Date:  2022-07-06       Impact factor: 20.999

5.  Invasive meningococcal disease in Italy: from analysis of national data to an evidence-based vaccination strategy.

Authors:  S Igidbashian; L Bertizzolo; A Tognetto; C Azzari; P Bonanni; P Castiglia; M Conversano; S Esposito; G Gabutti; G Icardi; P L Lopalco; F Vitale; S Parisi; G Checcucci Lisi
Journal:  J Prev Med Hyg       Date:  2020-07-04

Review 6.  Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.

Authors:  Federico Martinón-Torres; Muhamed-Kheir Taha; Markus Knuf; Victoria Abbing-Karahagopian; Michele Pellegrini; Rafik Bekkat-Berkani; Véronique Abitbol
Journal:  Pathog Glob Health       Date:  2021-09-27       Impact factor: 2.894

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.